Aeterna Zentaris to Present at the 2022 BIO CEO & Investor Conference
February 07 2022 - 7:05AM
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the
“Company”), a specialty biopharmaceutical company developing and
commercializing a diversified portfolio of pharmaceutical and
diagnostic products, today announced that Dr. Klaus Paulini, Chief
Executive Officer of Aeterna Zentaris, will present at the BIO CEO
& Investor Conference being held in New York, NY and virtually,
February 14-17, 2022.
In addition to the presentation, management will
be available to participate in virtual one-on-one meetings with
qualified members of the investor community who are registered to
attend the conference. For more information about the conference,
please visit the conference website.
A video webcast of the presentation will be
available for viewing on-demand for those registered for the
event.
About Aeterna Zentaris
Inc.Aeterna Zentaris is a specialty biopharmaceutical
company developing and commercializing a diversified portfolio of
pharmaceutical and diagnostic products focused on areas of
significant unmet medical need. The Company's lead product,
macimorelin (Macrilen™), is the first and only U.S. FDA and
European Commission approved oral test indicated for the diagnosis
of adult growth hormone deficiency (AGHD). The Company is
leveraging the clinical success and compelling safety profile of
macimorelin to develop it for the diagnosis of childhood-onset
growth hormone deficiency (CGHD), an area of significant unmet
need, in collaboration with Novo Nordisk.
Aeterna Zentaris is dedicated to the development
of therapeutic assets and has recently taken steps to establish a
growing pre-clinical pipeline to potentially address unmet medical
needs across a number of indications, including neuromyelitis
optica spectrum disorder (NMOSD), Parkinson’s disease (PD),
hypoparathyroidism and amyotrophic lateral sclerosis (ALS; Lou
Gehrig's disease). Additionally, the Company is developing an oral
prophylactic bacterial vaccine against SARS-CoV-2 (COVID-19) and
Chlamydia trachomatis.For more information, please visit
www.zentaris.com and connect with the Company on Twitter, LinkedIn
and Facebook.
Investor Contact:
Jenene ThomasJTC TeamT (US): +1 (833) 475-8247E:
aezs@jtcir.com
Aeterna Zentaris (TSX:AEZS)
Historical Stock Chart
From Apr 2024 to May 2024
Aeterna Zentaris (TSX:AEZS)
Historical Stock Chart
From May 2023 to May 2024